Pfizer News | finanzen.ch

Pfizer Aktie VALOR 1065272 / ISIN ARDEUT111424

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

02.11.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
02.11.23	Die Top 10 der grössten Übernahmen der Geschichte (finanzen.ch) AT&T, Pfizer und die Walt Disney Company haben eines gemeinsam: Sie zahlten hohe Summen, um andere Konzerne zu übernehmen.» mehr
31.10.23	Pfizer Reports Third-Quarter 2023 Results (Businesswire)
26.10.23	Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19 (RSS)
26.10.23	Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19 (Businesswire)
20.10.23	FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents (Businesswire)
13.10.23	Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance (Businesswire)
12.10.23	U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer (Businesswire)
05.10.23	Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases (Businesswire)
04.10.23	Pfizer Declares Fourth-Quarter 2023 Dividend (Businesswire)
28.09.23	Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine (RSS)
22.09.23	Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV (Businesswire)
19.09.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
19.09.23	European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata (Businesswire)
18.09.23	Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts (Businesswire)
12.09.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
11.09.23	Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine (RSS)
11.09.23	Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine (Businesswire)
05.09.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
30.08.23	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union (RSS)
30.08.23	Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences (Businesswire)
30.08.23	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union (Businesswire)
24.08.23	European Commission Approves Pfizer’s ABRYSVO™ to Help Protect Infants through Maternal Immunization and Older Adults from RSV (Businesswire)
21.08.23	U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age (Businesswire)
14.08.23	Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma (Businesswire)
01.08.23	Pfizer Reports Second-Quarter 2023 Results (Businesswire)
27.07.23	Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy (Businesswire)
21.07.23	Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility (Businesswire)
19.07.23	Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate (Businesswire)
14.07.23	There is no Alternative-Investmentansatz: Das steckt hinter der TINA-Strategie (finanzen.ch) Das griffige Kürzel TINA - There is no Alternative - genoss in den letzten Jahren in Börsenkreisen Hochkonjunktur. Experten erklärten mit TINA die Börsen-Hausse, Vermögensverwalter rieten mit TINA zum Aktienkauf und junge Trader riefen mit TINA zum Kauf von Meme-Aktien auf. Doch was genau steckt hinter diesen ominösen Buchstaben? Und welche Risiken bestehen bei dem Ansatz?» mehr
28.06.23	FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency (Businesswire)
27.06.23	FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec (Businesswire)
26.06.23	Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus (Businesswire)
23.06.23	FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata (Businesswire)
23.06.23	Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine (RSS)
23.06.23	Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine (RSS)
22.06.23	Pfizer Declares Third-Quarter 2023 Dividend (Businesswire)
21.06.23	Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval (Businesswire)
20.06.23	Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts (Businesswire)
06.06.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
01.06.23	Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options (Businesswire)
31.05.23	U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults (Businesswire)
30.05.23	Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial (Businesswire)
26.05.23	Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission (RSS)
25.05.23	Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting (Businesswire)
25.05.23	Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19 (Businesswire)
18.05.23	FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization (Businesswire)
17.05.23	Pfizer Prices $31,000,000,000 Debt Offering (Businesswire)
15.05.23	Pfizer Announces Proposed Notes Offering (Businesswire)
02.05.23	Pfizer Reports First-Quarter 2023 Results (Businesswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	97.48	2.68 %	K V
Part Grp Hldg	967.00	2.59 %	K V
ABB	57.08	1.71 %	K V
Holcim	71.46	1.59 %	K V
Roche Hldg G	272.60	1.56 %	K V
Nestle	79.15	0.04 %	K V
Novartis	101.94	-0.06 %	K V
Zurich Insur Gr	564.40	-0.39 %	K V
Swiss Life Hldg	869.60	-0.44 %	K V
Swisscom	595.50	-1.24 %	K V